Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Apalutamide

FDA-approved product (tablet, oral), marketed as Apalutamide, Erleada.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Apalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Anti-androgens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Apalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Apalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

    NCT07645326 · start 2026-08

    Registered record
    Registry ID
    NCT07645326
    Conditions
    Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
    Interventions
    Androgen Deprivation Therapy (ADT); Androgen Receptor Pathway Inhibitor (ARPI); Prostate Radiation; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08
    Completion
    2032-08
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Hormone-sensitive Prostate Cancer (mHSPC)
    InterventionAndrogen Deprivation Therapy (ADT); Androgen Receptor Pathway Inhibitor (ARPI); Prostate Radiation; Docetaxel
    PhasePhase 2
    Registry statusNot yet recruiting

  • Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

    NCT07333066 · start 2026-06-05

    Registered record
    Registry ID
    NCT07333066
    Conditions
    Metastatic Hormone-sensitive Prostate Cancer
    Interventions
    Apalutamide (Erleada™) 60 mg or 240 mg tablets; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-06-05
    Completion
    2030-03-31
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Hormone-sensitive Prostate Cancer
    InterventionApalutamide (Erleada™) 60 mg or 240 mg tablets; Docetaxel
    PhasePhase 3
    Registry statusRecruiting

  • Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    NCT07389174 · start 2026-02

    Registered record
    Registry ID
    NCT07389174
    Conditions
    mHSPC; mHNPC; Prostate Cancer Adenocarcinoma
    Interventions
    Standard Endocrine Therapy; LC-K76
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-02
    Completion
    2027-06
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionmHSPC; mHNPC; Prostate Cancer Adenocarcinoma
    InterventionStandard Endocrine Therapy; LC-K76
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

    NCT06931340 · start 2025-12-01

    Registered record
    Registry ID
    NCT06931340
    Conditions
    Castration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Androgen Therapy; Apalutamide; Docetaxel; Computed Tomography; Magnetic Resonance Imaging; Bone Scan; PSMA PET Scan; Biospecimen Collection; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-01
    Completion
    2039-05-08
    Enrolment
    1,260

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCastration-Sensitive Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionAndrogen Therapy; Apalutamide; Docetaxel; Computed Tomography +5 more
    PhasePhase 3
    Registry statusRecruiting

  • CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

    NCT07268794 · start 2025-11-30

    Registered record
    Registry ID
    NCT07268794
    Conditions
    Metastatic Prostate Cancer; Prostate Cancer (Adenocarcinoma); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Interventions
    Androgen Deprivation Therapy (ADT); Docetaxel; PARP Inhibitors and Other Systemic Agents; Radical Prostatectomy; Prostate Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-11-30
    Completion
    2027-12-30
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer; Prostate Cancer (Adenocarcinoma); Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    InterventionAndrogen Deprivation Therapy (ADT); Docetaxel; PARP Inhibitors and Other Systemic Agents; Radical Prostatectomy +1 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

    NCT06894511 · start 2025-09-11

    Registered record
    Registry ID
    NCT06894511
    Conditions
    Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Interventions
    AAA617; ARPI: Abiraterone; ARPI: Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-09-11
    Completion
    2026-10-15
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration Resistant Prostate Cancer (mCRPC)
    InterventionAAA617; ARPI: Abiraterone; ARPI: Enzalutamide
    PhasePhase 2
    Registry statusActive not recruiting

  • Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

    NCT06832774 · start 2025-08-01

    Registered record
    Registry ID
    NCT06832774
    Conditions
    Prostate Cancer Metastatic Disease
    Interventions
    Local treatment; Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-01
    Completion
    2028-12-31
    Enrolment
    192

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic Disease
    InterventionLocal treatment; Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide).
    PhasePhase 2
    Registry statusRecruiting

  • Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database

    NCT06902441 · start 2025-01-07

    Registered record
    Registry ID
    NCT06902441
    Conditions
    Prostate Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-01-07
    Completion
    2025-06-30
    Enrolment
    52,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

    NCT06496581 · start 2024-09-12

    Registered record
    Registry ID
    NCT06496581
    Conditions
    Prostate Cancer Metastatic
    Interventions
    177Lu-PMSA-617; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-09-12
    Completion
    2039-08-01
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    Intervention177Lu-PMSA-617; Standard of Care
    PhasePhase 3
    Registry statusRecruiting

  • Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

    NCT06992232 · start 2024-08-01

    Registered record
    Registry ID
    NCT06992232
    Conditions
    Prostate Cancer Metastatic Disease
    Interventions
    Intense androgen deprivation therapy; Radiation Therapy; radical prostatectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-08-01
    Completion
    2028-07-31
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic Disease
    InterventionIntense androgen deprivation therapy; Radiation Therapy; radical prostatectomy
    PhasePhase 2
    Registry statusRecruiting

  • A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

    NCT06095089 · start 2023-11-01

    Registered record
    Registry ID
    NCT06095089
    Conditions
    Prostatic Neoplasms
    Interventions
    JNJ-78278343; JNJ-87189401; Apalutamide; Lutetium Lu-177 Vipivotide Tetraxetan; JNJ-101556143
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-11-01
    Completion
    2028-06-28
    Enrolment
    355

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms
    InterventionJNJ-78278343; JNJ-87189401; Apalutamide; Lutetium Lu-177 Vipivotide Tetraxetan +1 more
    PhasePhase 1
    Registry statusRecruiting

  • Impact of Apalutamide in Metastatic Hormone Sensitive Prostate Cancer Patients

    NCT06019676 · start 2023-09-26

    Registered record
    Registry ID
    NCT06019676
    Conditions
    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2023-09-26
    Completion
    2027-04-01
    Enrolment
    170

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    InterventionNot recorded
    PhaseNot recorded
    Registry statusActive not recruiting

  • Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC

    NCT05771896 · start 2023-09

    Registered record
    Registry ID
    NCT05771896
    Conditions
    Metastatic Prostate Cancer
    Interventions
    Darolutamide; Radium-223
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2023-09
    Completion
    2029-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    InterventionDarolutamide; Radium-223
    PhasePhase 3
    Registry statusWithdrawn

  • A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

    NCT05884398 · start 2023-08-31

    Registered record
    Registry ID
    NCT05884398
    Conditions
    Metastatic Castrate-sensitive Prostate Cancer
    Interventions
    Apalutamide; Androgen-deprivation Therapy (ADT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-08-31
    Completion
    2028-10-12
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castrate-sensitive Prostate Cancer
    InterventionApalutamide; Androgen-deprivation Therapy (ADT)
    PhasePhase 3
    Registry statusActive not recruiting

  • Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

    NCT06145308 · start 2023-08-15

    Registered record
    Registry ID
    NCT06145308
    Conditions
    Salivary Gland Carcinoma; Precision Therapy
    Interventions
    Cohort 1 (HER2-positive, RC48-ADC); Cohort 2 (NTRK-fusion or NTRK-mutant); Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone); TROP2 ADC; TKI; Albumin-paclitaxel + platinum; Albumin-paclitaxel + carboplatin + apatinib + camrelizumab; albumin-bound paclitaxel+trastuzumab+pyrotinib; HER2,trastuzumab deruxtecan± pertuzumab; AR,AR antagonist ++ goserelin + pertuzumab + trastuzumab; AR,AR antagonist +goserelin +docetaxel; ivonescimab + investigator-choice platinum doublet+; iparomlimab + tuvonralimab; cadonilimab; CDK4/6 inhibitor+AI or fulvestrant; alpelisib+fulvestrant; PARP inhibitor; enfortumab vedotin; HER2, pyrotinib + pertuzumab/trastuzumab; vebecotutamab ±lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-08-15
    Completion
    2028-07-10
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSalivary Gland Carcinoma; Precision Therapy
    InterventionCohort 1 (HER2-positive, RC48-ADC); Cohort 2 (NTRK-fusion or NTRK-mutant); Cohort 3 (AR-positive, leuprolide + bicalutamide + abiraterone); TROP2 ADC +16 more
    PhasePhase 2
    Registry statusRecruiting